COVID-19 Rapid Antigen Test Provides End-to-End Digital Screening Solution

A new COVID-19 antigen test provides a full end-to-end digital screening solution to prevent further outbreaks.

iXensor’s (Taipei, Taiwan) PixoTest POCT COVID-19 Antigen Test has received the CE-IVD mark. The iXensor’s PixoTest solution comprises a palm-sized analyzer that reads test results accurately, a digital health pass App, an Admin App, and a HIPAA-grade health management web portal. The fully digitized testing and reporting design shortens the test-to-report time to 15 minutes. In addition to overcoming the lab testing limitations, the solution allows for scaling in large screening settings, thereby enabling business continuity and reopening.

With the PixoTest POCT Analyzer reading test results objectively, healthcare organizations and corporations can minimize the risks of having false-negative cases compared to rapid tests interpreted by human eyes. The analyzer transmits test results simultaneously to the PixoHealth Pass App users via an encrypted QR code. The digital health pass also records App users’ vaccination certificates, helping free movement in the upcoming summer holiday season. The PixoHealth Pass Admin App is designed for organizations to verify the authenticity of PixoTest test results with one simple scan. The admin app protects organizations’ safety amidst the pandemic by validating the cheat-proof, encrypted results shown on PixoHealth Pass App.

“We are deploying iXensor’s core PixoTech technology to develop the smartphone-based self-test that can perform COVID-19 testing and tracking, anywhere at any time,” said Dr. Peter Fitzgerald, Chairman of iXensor and Emeritus Professor of Medicine School at Stanford University. “I believe having COVID-19 at-home test will drastically cut many transmission paths to stop the pandemic.”

Related Links:
iXensor